Search

Displaying results 3321 - 3330 of 7603 in total
  1. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. … LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway.

  2. Drug

    Lonidamine

    go.drugbank.com/drugs/DB06266
    Investigational

    Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK).

  3. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. … Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD.

  4. Drug

    SPL84-23-1

    go.drugbank.com/drugs/DB18575
    Experimental

    SPL84-23-1 is a sodium salt of 19-bp single-stranded RNA uniformly modified 2'-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence

  5. Indication

    Mucopolysaccharidosis Type I (MPS I)

    go.drugbank.com/conditions/DBCOND0065667
    Drugs: Laronidase
    Synonyms: Mucopolysaccharidosis type I severe form, Mucopolysaccharidosis type I mild form
  6. Drug

    Albumin iodinated I-131 serum

    go.drugbank.com/drugs/DB09430
    Approved

    Iodinated I-131 serum albumin is a radiopharmaceutical agent used for several diagnostic purposes, including the determination of body fluid volumes and the imaging of certain tissues.[L12783]

  7. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  8. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Hydroxyamphetamine

    go.drugbank.com/drugs/DB09352
    Approved

    Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. … Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary

  10. Drug

    Ezatiostat

    go.drugbank.com/drugs/DB05460
    Investigational

    These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen … Ezatiostat is investigated in clinical trials for treating myelodysplastic syndrome. This compound belongs to the peptides.